A committee of independent experts advising the Centers for Disease Control and Prevention is set to vote Tuesday whether to recommend the Pfizer vaccine for children 5-11, checking off one of the last boxes in the authorization process.

If members of the committee vote to recommend use of the vaccine, CDC Director Rochelle Walensky is expected to then issue a recommendation as soon as Tuesday evening, the final step in the process, which would allow the first shots to be administered as soon as Wednesday morning.

But vaccinations are not expected to kick into high-gear until Nov. 8, when the White House says Pfizer’s pediatric vaccines will be more widely accessible across the nation.

About 15 million doses are expected to ship out over the next week. The majority, about 10 million, will be available at pediatrician’s offices, children’s hospitals, community centers and mass vaccination sites. About 5 million doses will go to pharmacies.

Many parents are anxious to protect their children after the delta surge over the summer led to increased cases and hospitalizations among kids. Though the variant is not more deadlier, it is more transmissible — and because kids are unvaccinated, the variant rocketed through schools and camps.

The most recent data from Pfizer’s clinical trials found that the vaccine for children ages 5-11 was nearly 91% effective against symptomatic illness.

For kids, the vaccine will be given at a smaller, one-third dose.

The vaccine also appears safe. The company says none of the children in clinical trials experienced a rare heart inflammation side effect known as myocarditis, which has been associated with the mRNA vaccines in very rare cases, mostly among young men.

Last week, all of the efficacy and safety data was reviewed by a panel of experts at the Food and Drug Administration, which then voted nearly-unanimously to authorize the vaccine.

Though there was some debate at the FDA advisory meeting about the potential side effects for children ages 5-11, though none were experienced by any of the 3,100 kids ages 5-11 in the trial, the panel decided any the potential risk was worth the benefit.

Then, last Friday, the vaccine was authorized by FDA acting commissioner Janet Woodcock.

Whether parents will embrace the vaccine for their kids is still a question. In an October poll, the Kaiser Family Foundation found that about a third of parents with kids ages 5-11 were willing to vaccinate their kids right away, while another third wanted to “wait and see.” The figures represented a slight uptick in vaccine acceptance among parents of elementary-school-aged kids since July, but they have stayed steady since September.

Woodcock told reporters on Friday that she hoped parents would quickly see the benefits.

“We certainly hope that as people see children getting vaccinated and being protected, being able to participate in activities without concern, that more and more people will get their kids vaccinated,” she said.

And she emphasized the urgency of preventing the conditions that can come with COVID diagnoses in kids.

“As a parent, if I had young children this age group I would get them vaccinated now. I would not want to take the risk that they would be one of the ones who would develop long COVID, who would develop multi-system inflammatory syndrome or have to be hospitalized from from the virus,” Woodcock said.

ABC News’ Sasha Pezenik and Anne Flaherty contributed to this report.